NanoViricides Inc. (NNVC)
| Bid | 1.45 |
| Market Cap | 23.95M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.73M |
| EPS (ttm) | -0.69 |
| PE Ratio (ttm) | -2.16 |
| Forward PE | -1.42 |
| Analyst | Buy |
| Ask | 1.51 |
| Volume | 115,892 |
| Avg. Volume (20D) | 263,532 |
| Open | 1.48 |
| Previous Close | 1.47 |
| Day's Range | 1.44 - 1.50 |
| 52-Week Range | 0.94 - 2.34 |
| Beta | 0.96 |
About NNVC
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for NNVC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
2 weeks ago · proactiveinvestors.com
NanoViricides says antiviral candidate NV-387 could address global measles surgeNanoViricides (NYSE-A:NNVC) said on Wednesday that its antiviral candidate NV-387 could play a key role in addressing the growing number of measles cases globally, particularly in industrialized natio...
3 weeks ago · proactiveinvestors.com
NanoViricides eyes revenue opportunities with broad-spectrum antiviral NV-387NanoViricides (NYSE-A:NNVC) said on Wednesday that its broad-spectrum antiviral candidate NV-387 has shown strong preclinical efficacy against multiple viruses, positioning it as a potential tool in g...
3 weeks ago · proactiveinvestors.com
NanoViricides says lead antiviral boosted survival in measles-infected miceNanoViricides (NYSE-A:NNVC) said on Monday that its broad-spectrum antiviral candidate, NV-387, showed strong effectiveness in preclinical studies using a humanized animal model. The Connecticut-based...
1 month ago · proactiveinvestors.com
NanoViricides says MPox drug candidate NV-387 poised for Phase II trial as WHO extends global health emergencyNanoViricides (NYSE-A:NNVC) is preparing for Phase II clinical testing in Africa, following the World Health Organization's recent extension of the Public Health Emergency of International Concern (PH...
1 month ago · proactiveinvestors.com
NanoViricides positioned at forefront of Mpox treatment efforts, says ZacksNanoViricides (NYSE-A:NNVC) is preparing to launch a Phase 2 clinical trial of its lead antiviral candidate NV-387 for the treatment of Mpox Clade I in the Democratic Republic of Congo (DRC), followin...
1 month ago · proactiveinvestors.com
NanoViricides nears completion of clinical trial design for MPox treatmentNanoViricides (NYSE-A:NNVC) said on Monday it is close to finalizing the design of a Phase II adaptive clinical trial for its lead candidate NV-387 to treat MPox virus Clade 1a and 1b infections. The ...